May 2023 in “Research Square (Research Square)” In this study, researchers observed that treatment with Agaricus subrufescens ethanolic extract improved blood glucose, testosterone levels, and menstrual irregularity in rat models of letrozole-induced Polycystic Ovarian Syndrome, also noting a decrease in elevated liver and ovary weights, suggesting protective effects on renal function.
1 citations
,
November 2023 in “Journal of ovarian research” In this study involving rats with letrozole-induced polycystic ovary syndrome, Agaricus subrufescens significantly reduced blood glucose, total cholesterol, testosterone levels, and renal markers, suggesting its potential protective effects on both metabolic and reproductive parameters.
March 2026 in “Inflammopharmacology” This study found that ursolic acid at 50 mg/kg improved biochemical, hormonal, and ovarian histopathological markers in a rat model of PCOS, suggesting its potential as a therapeutic option.
October 2024 in “bioRxiv (Cold Spring Harbor Laboratory)” This study examined lipid changes in rat models of polycystic ovarian syndrome, finding that letrozole and dihydrotestosterone treatments led to some lipid alterations similar to human PCOS, while other changes were unique to the models.
April 2017 in “Journal of Pharmaceutical Investigation” In this study, the administration of indole-based compounds, particularly L-Tryptophan and Tryptophol, to a PCOS-induced rat model resulted in an increased number of healthy ovarian follicles and a reduction in ovarian cysts compared to untreated rats, suggesting potential therapeutic efficacy.